Small dense LDL cholesterol (sdLDL-c) is an important biomarker for understanding a patient's risk of coronary heart disease. In this test-specific episode of the "Answers From the Lab" podcast, Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' assay measuring sdLDL-c concentrations aids clinical management of patients with high LDL or "bad" cholesterol.

"sdLDL-c is a particular type of harmful cholesterol that is thought to be highly atherogenic," Dr. Vasile says. "Patients with elevated LDL cholesterol might or might not have high small dense LDL. The sdLDL-c assay identifies the category of patients at higher risk, who might otherwise be missed in clinical practice."

The results can directly impact clinical care.

"The higher the cholesterol concentration in these small dense particles, the higher the risk of future cardiovascular events," Dr. Donato says. "sdLDL-c test results can help guide decisions about initiating or intensifying a pharmacotherapy, to lower overall atherosclerotic cardiovascular disease risk."

Listen to learn more about Mayo Clinic Laboratories' sdLDL-c assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

SDLDL   | Small Dense Low Density Lipoprotein Cholesterol, Serum

Useful information

Aiding in risk management of lipoprotein disorders associated with cardiovascular disease when used in conjunction with other lipid measurements and clinical evaluation.

Specimen requirements

Patient Preparation: Fasting: Overnight (8-12 hours)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Centrifuge and aliquot serum into a plastic vial.
2. Send frozen.

Performance information

• Analytic time: 1 - 3 days
• Day(s) and time(s) performed: Monday through Sunday

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less